Iron Supplementation in Pediatric Iron Deficiency Anemia

Indications and Treatment Approaches

The American Academy of Pediatrics recommends iron sucrose for children with chronic kidney disease from age 2 years, with no test dose required, making it safer and more convenient than iron dextran 2
For pediatric patients who fail oral iron, intravenous iron formulations, particularly iron sucrose or ferric gluconate, should be considered, as IV iron demonstrates superior efficacy with acceptable safety profiles in children aged 6 years and older, with 65% responding to IV iron versus only 21% who continue oral iron 1
The American Journal of Hematology suggests that failure to respond to oral iron after 14 days, intolerance to oral iron, chronic kidney disease requiring hemodialysis, malabsorption conditions, or functional iron deficiency with inflammation are indications for IV iron 1

Iron sucrose is the preferred IV iron formulation for ages 2+ years, with a recommended dosing of maximum 200 mg per slow IV infusion, and a lower risk of severe adverse events compared to iron dextran 3
Ferric gluconate is FDA-approved for ages 6+ years, with a recommended dosing of 0.12 mL/kg (1.5 mg/kg elemental iron) diluted in 25 mL 0.9% saline, infused over 1 hour per dialysis session, and no test dose required 2
Low molecular weight iron dextran is the only iron formulation FDA-approved for pediatric patients <6 years when oral iron fails, but requires a test dose due to anaphylaxis risk 3

A 2021 meta-analysis found IV iron associated with increased infection risk, which must be balanced against benefits of treating anemia and reducing transfusion requirements 5
The Journal of the National Comprehensive Cancer Network recommends not administering iron supplementation to patients with active infection 6
Regular monitoring of iron status (ferritin, transferrin saturation) is necessary to prevent iron overload, and monitoring patients during and for at least 30 minutes after IV iron administration is required until clinically stable 2

For patients with chronic kidney disease, IV iron is preferred over oral iron due to impaired absorption, and enteral iron is preferred when adequate iron status can be maintained, but parenteral iron is recommended when enteral supplements fail 2
For patients with absolute iron deficiency, IV iron monotherapy without erythropoietin-stimulating agents is appropriate, and for patients with functional iron deficiency, consider IV iron with concurrent erythropoietin therapy in specific contexts 6